Sponsors (18)
The bill increases safety and transparency by requiring allergen and gluten disclosures on drug labels—helping patients and providers avoid exposures—at the cost of added compliance and testing expenses for manufacturers and additional enforcement burdens for regulators.
People with food allergies, celiac disease, or gluten sensitivity (and the hospitals and pharmacies that serve them) can avoid accidental exposures because drug labels must disclose major food allergens and specify which gluten-containing grains are present.
All consumers and patients gain clearer information about drug contents, improving transparency and enabling more informed choices about medications.
Drug manufacturers (and ultimately consumers) may face higher costs because companies must redesign labels and perform ingredient tracing/testing, which could lead to higher drug prices.
Small and generic drug manufacturers face compliance and transition burdens from labeling changes during the implementation window, creating financial and operational strain on smaller firms.
Patients may still be confused by ambiguous disclosures for complex or indirectly derived ingredients, risking misunderstanding despite increased labeling.
Based on analysis of 2 sections of legislative text.
Requires prescription and over-the-counter human drug labels to disclose if the product contains major food allergens or ingredients derived from them, and to identify gluten-containing grains (wheat, barley, rye, and crossbred hybrids) when present. Labels must list each such ingredient and, when applicable, specify the type of gluten-containing grain. The rule takes effect on a date set by the HHS Secretary or, if earlier, two years after enactment.
Introduced June 6, 2025 by Kelly Morrison · Last progress June 6, 2025